pro-542
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000876)
Timeline
Indications
Mechanism of action
- Envelope glycoprotein gp160INHIBITOR
Q6QLK5 inhibitor
Blocking its attachment to CD4 cells. Immunoprophyaxis HIV1 infection.
- Envelope glycoprotein gp160INHIBITOR
Q993A8 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109442 ↗
Also known as
- cd4 igg2
- cd4-igg2
- cd4-igg(2)
- pro 542
- pro 542
- pro-542
- pro-542
- pro-542
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00055185 | Phase 2 | Apr 1, 2003 | Icahn School of Medicine at Mount Sinai, Progenics |
| NCT00000876 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2003 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 1999 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 1999 |
| Progenics | For profit | 1 | 1 | 1 | 2003 |
4 organizations
Page 1 / 1